Promising Three-Drug cocktail shows strong results in multiple myeloma
NCT ID NCT07206810
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This completed study tested a combination of three drugs—bortezomib, lenalidomide, and dexamethasone (VRD)—in 419 newly diagnosed multiple myeloma patients. Some patients also received a stem cell transplant. The goal was to see how well the treatment worked and how long patients lived. The study found that the VRD regimen led to good response rates, but long-term follow-up is needed to confirm lasting benefits.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
bortezomib, lenalidomide, and dexamethasone (VRD)
What this could lead to
If successful, this regimen could become a standard first-line treatment for newly diagnosed multiple myeloma, improving response rates and extending survival.
What could go wrong
This is a single-center, real-world registry study, not a randomized controlled trial. Results may not apply to all patients, and long-term side effects of the drugs (e.g., nerve damage, blood clots) are possible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYELOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
First Affiliated Hospital, Soochow University
Suzhou, Jiangsu, 215000, China